Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks
GH Secretagogue (GHRP)

MK-677 (Ibutamoren) — Oral Ghrelin-Receptor Agonist (Research Evidence Summary)

Research evidence summary

also known as Ibutamoren, MK-0677, L-163,191

MK-677 (ibutamoren) is an oral, non-peptide ghrelin-receptor agonist. This summary reviews the randomised trial evidence, the heart failure and glucose signals, and what is unknown.

Sequence
Non-peptide small molecule (piperidine derivative)
MW
528.7 Da (free base)
Discovered
1990s
Receptor
Growth hormone secretagogue receptor (GHS-R1a, the ghrelin receptor)
Half-life
Not established in humansNo source checked
Routes in study
Oral
Save

What MK-677 is

MK-677 (also written MK-0677; international name ibutamoren; development code L-163,191) is a small-molecule agonist at the growth hormone secretagogue receptor (GHS-R1a), the receptor ghrelin activates. It is not a peptide and is taken by mouth; the trials describe it as an orally active ghrelin mimetic (PMID 18981485). In healthy older adults it increased growth hormone (GH) through "an enhancement of preexisting pulsatile GH secretion": pulse height and the low points between pulses rose without a significant change in the number of pulses (PMID 8954023).

Evidence from trials

The trials were mostly in older or unwell people. Adult doses were taken by mouth once daily; 25 mg was the most studied.

  • Healthy older adults, 14 and 28 days (PMID 8954023). 32 adults aged 64 to 81 took placebo or 2, 10 or 25 mg. At 25 mg, mean 24-hour GH rose 97% and serum IGF-I (insulin-like growth factor I) rose into the young-adult range (141 µg/L at baseline, 265 at 4 weeks). Fasting glucose rose from 5.4 to 6.8 mmol/L (P < 0.01). Cortisol did not change; prolactin rose 23% but stayed within the normal range.
  • Healthy young men, 7 days (PMID 8768828). Nine men took 5 or 25 mg at bedtime; IGF-I rose dose-dependently and 24-hour mean cortisol levels were similar under all conditions.
  • GH-deficient men, 4 days (PMID 9329386). Nine men aged 17 to 34 took 10 or 50 mg; IGF-I rose 52% at 10 mg and 79% at 50 mg.
  • Calorie restriction (PMID 9467534). Eight healthy volunteers took 25 mg or placebo for the last 7 days of two 14-day calorie-restricted periods. Mean nitrogen balance was 0.31 g/day on MK-677 and -1.48 g/day on placebo (P < 0.01).
  • Obese men, 8 weeks (PMID 9467542). 24 men took 25 mg or placebo. IGF-I rose about 40% and fat-free mass rose, but total and visceral fat did not change significantly. Fasting glucose and insulin were unchanged, yet an oral glucose tolerance test showed impaired glucose handling at 2 and 8 weeks.
  • Healthy older adults, 2-year design (PMID 18981485). 65 adults aged 60 to 81 took 25 mg or placebo; the primary end points were fat-free mass and abdominal visceral fat after 1 year. Fat-free mass changed by +1.1 kg on MK-677 and -0.5 kg on placebo, but there was no significant difference in visceral fat or total fat, and limb fat rose more on MK-677. "Increased fat-free mass did not result in changes in strength or function", and two-year exploratory analyses confirmed the 1-year results. Body weight rose 2.7 kg against 0.8 kg. Fasting glucose rose by an average of 0.3 mmol/L (P = 0.015) and insulin sensitivity decreased. The most frequent side effects were increased appetite that eased within months, and transient, mild leg oedema and muscle pain. Cortisol rose 47 nmol/L. The authors noted the study was underpowered for functional end points.
  • Alzheimer's disease, 12 months (PMID 19015485). In 563 patients with mild to moderate disease, 25 mg raised serum IGF-1 by 60.1% at 6 weeks and 72.9% at 12 months, but there were no significant differences from placebo on four standard dementia rating scales (CIBIC-plus, ADAS-Cog, ADCS-ADL and CDR-sob). The authors concluded it was ineffective at slowing progression.
  • Hip fracture, 24 weeks (PMID 21067829). In 123 elderly patients, 25 mg/day (62 patients) or placebo (61), IGF-1 rose by 51.4 ng/ml against placebo. Stair-climbing power did not change significantly (p = 0.292), gait speed did (p = 0.011), and other performance measures did not improve. The trial was terminated early because of a safety signal of congestive heart failure in a limited number of patients, and the authors concluded MK-0677 had an unfavourable safety profile in this population.
  • Women with low bone density, 18-month study (PMID 11238495). 292 women aged 64 to 85 took MK-677 25 mg with or without alendronate 10 mg, or alendronate or placebo, for 12 months; those on MK-677 alone or placebo then took the combination for months 12 to 18. MK-677 plus alendronate raised femoral neck bone mineral density more than alendronate alone (4.2% against 2.5%), but not at the lumbar spine, total hip or total body. The authors called the lack of enhancement at other sites a concern when weighed against the potential side effects of enhanced GH secretion. In healthy and functionally impaired older adults, bone-turnover markers rose (PMID 10404019).
  • Children (PMID 11452249). 18 children with GH deficiency took 0.2 or 0.8 mg/kg a day for 7 days. Doses in children are per kilogram and are not adult doses.

Registered trials

  • Fatty liver (NCT05364684). A phase 2 open-label study of ibutamoren mesylate (LUM-201) 25 mg daily in 12 adults with a body mass index (BMI) of 25 or more and fatty liver disease posted results in January 2026. Seven of the 12 completed 6 months. Liver fat, the primary outcome, rose by 3.9 percentage points (standard deviation 6.7) against 6.6 (6.1) in 10 historical placebo participants (p = 0.4); a liver inflammation and fibrosis score (cT1, measured by MRI) rose by 39 ms against 44 ms (p = 0.9); ALT, a liver enzyme, rose by 8 U/L against 4 (p = 0.6). No serious adverse events were posted; all 12 had other adverse events, including increased appetite (7), hyperglycaemia (4), upper respiratory infection (4), fatigue (3) and joint pain (3).
  • Haemodialysis (NCT00395291; PMID 28340044). A randomised, blinded crossover study of MK-0677 against placebo (25 mg for about 30 days, per the registry) in people on haemodialysis. The paper says 26 subjects enrolled and 22 completed; the registry lists 49 enrolled. Geometric mean IGF-1 was 1.76-fold greater after MK-0677 and 1.07-fold after placebo (adjusted ratio 1.65, 95% CI 1.33 to 2.04). The registry posts serious adverse events in 4 of 26 participants on MK-0677 (renal failure, ischaemic colitis, an eroded dialysis graft, a catheter-line infection and congestive heart failure) and 3 of 26 on placebo, and other events in 5 of 26 against 0. The authors write that there were "no serious adverse effects attributable to MK-0677".
  • No posted results. NCT00116129 (fibromyalgia, 25 mg/day, 64 participants) is completed, with no results posted (ClinicalTrials.gov, 6 November 2026). NCT06948214, a phase 3 trial of LUM-201 1.6 mg/kg/day in children with GH deficiency, was recruiting on 6 November 2026.

Safety signals

  • FDA bulk drug substances page. FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (content current as of 22 April 2026) lists ibutamoren mesylate in category 2 under the 503A interim policy (added 29 September 2023) and the 503B interim policy (added 29 December 2022). Compounding is the preparation of a medicine by a pharmacist or doctor from its ingredients. FDA's entry for ibutamoren mesylate reads: "Ibutamoren mesylate poses significant safety risks due to the potential for congestive heart failure in certain patients. The agency is aware of a randomized, placebo-controlled trial assessing ibutamoren mesylate for the treatment of patients recovering from hip fracture that “was terminated early due to a potential safety signal of congestive heart failure.”"
  • Heart failure. The hip-fracture trial was stopped early over a congestive heart failure signal (PMID 21067829). In the dialysis crossover, one of the serious events on MK-0677 was congestive heart failure; its authors attribute none to MK-0677 (PMID 28340044). A 2026 review lists congestive heart failure among the significant risks associated with MK-677 (PMID 42578445).
  • Glucose. Fasting glucose rose in older adults, glucose handling was impaired in obese men, and 4 of 12 in the fatty-liver study had hyperglycaemia. A 2018 review noted some concern for rises in blood glucose because of decreases in insulin sensitivity (PMID 28400207).
  • Oedema, appetite, muscle pain and cortisol. Leg oedema, appetite and muscle pain were reported over a year in older adults; cortisol was unchanged over 4 weeks (PMID 8954023) but rose by 47 nmol/L (PMID 18981485).
  • Liver. A man in his early 30s developed transaminitis (raised liver enzymes) after taking MK-677 for 2 months; tests returned to normal after he stopped (PMID 40675653). A 25-year-old taking MK-677 15 mg and the selective androgen receptor modulator (SARM) LGD-4033 10 mg daily for 5 weeks had rises in the liver enzymes ALT (+205.0%) and AST (+95.8%) and falls in bone mineral density and testosterone; effects cannot be attributed to MK-677 alone (PMID 36303408).
  • Duration. Primary analyses covered up to 12 months of treatment; the longest design was 2 years (PMID 18981485). A 2018 review concluded that long-term safety, including cancer incidence and mortality, still needs to be studied (PMID 28400207).

Status and limits of the evidence

DailyMed name searches on 6 November 2026 returned no label for "MK-677", and two bulk-ingredient listings for "ibutamoren" (ibutamoren mesylate powder, 2016 and 2017, marked as bulk ingredient for animal drug compounding), which are not prescribing labels. The 2026 World Anti-Doping Agency Prohibited List names ibutamoren (MK-677) among the growth hormone secretagogues under S2.2.4, prohibited at all times (see peptides and sports anti-doping).

The main trials were in people aged 60 and over or in patients. None of the trial abstracts above reports a human half-life, and none was found in the PubMed search (MK-677 OR MK-0677 OR ibutamoren) AND (pharmacokinetic* OR half-life) of 3 November 2026. The nearest is a 1997 assay paper (PMID 9200526): its abstract says the method could map the pharmacokinetic time-course in human plasma after a single 5 mg oral dose, and reports the assay's validation range (0.1 to 100 ng/ml) but no half-life or other pharmacokinetic values.

UK regulatory position

This site gives no legal advice or sourcing information and does not sell anything. Rules on unauthorised medicines exist in the Human Medicines Regulations 2012. Whether a particular product is a medicinal product under regulation 2 depends on its specifics, including how it is presented and how it functions. For questions about medicines speak to a GP or pharmacist; problems with a medicine can be reported to the MHRA through the Yellow Card scheme.

Regulatory and clinical status

UK status: Investigational. No DailyMed label for MK-677 (name search, 6 November 2026). Ibutamoren mesylate (LUM-201) was recruiting for a phase 3 trial in children with growth hormone deficiency (NCT06948214). FDA safety statement: see Safety signals. Named under S2.2.4 of the WADA 2026 Prohibited List.

Read what UK official sources say about medicines in our UK regulation hub and our explanation of why “research grade” does not mean safe. PeptideStacks does not make editorial sourcing recommendations within research content; any vendor links elsewhere on this page appear in a clearly-labelled sponsor block (see our conflict-of-interest disclosure).

References

Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.

  1. Chapman IM, Bach MA, et al.. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology and Metabolism. 1996;81(12) :4249-4257 · PMID: 8954023
  2. Chapman IM, Pescovitz OH, Murphy G, et al.. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults. Journal of Clinical Endocrinology and Metabolism. 1997;82(10) :3455-63 · PMID: 9329386
  3. Copinschi G, Van Onderbergen A, L'Hermite-Balériaux M, et al.. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. Journal of Clinical Endocrinology and Metabolism. 1996;81(8) :2776-82 · PMID: 8768828
  4. Murphy MG, Plunkett LM, et al.. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. Journal of Clinical Endocrinology and Metabolism. 1998;83(2) :320-325 · PMID: 9467534
  5. Svensson J, Lönn L, Jansson JO, et al.. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology and Metabolism. 1998;83(2) :362-9 · PMID: 9467542
  6. Murphy MG, Bach MA, et al. (MK-677 Study Group). Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. Journal of Bone and Mineral Research. 1999;14(7) :1182-1188 · PMID: 10404019
  7. Murphy MG, Weiss S, et al.. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. Journal of Clinical Endocrinology and Metabolism. 2001;86(3) :1116-1125 · PMID: 11238495
  8. Codner E, Cassorla F, Tiulpakov AN, et al.. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clinical Pharmacology and Therapeutics. 2001;70(1) :91-8 · PMID: 11452249
  9. Nass R, Pezzoli SS, Oliveri MC, et al.. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine. 2008;149(9) :601-11 doi:10.7326/0003-4819-149-9-200811040-00003 · PMID: 18981485
  10. Sevigny JJ, Ryan JM, van Dyck CH, et al.. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008;71(21) :1702-8 doi:10.1212/01.wnl.0000335163.88054.e7 · PMID: 19015485
  11. Adunsky A, Chandler J, Heyden N, et al.. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Archives of Gerontology and Geriatrics. 2011;53(2) :183-9 doi:10.1016/j.archger.2010.10.004 · PMID: 21067829
  12. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews. 2018;6(1) :45-53 · PMID: 28400207
  13. Cardaci TD, Machek SB, et al.. LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental Physiology. 2022;107(12) :1467-1476 · PMID: 36303408
  14. Cobani E, Amin MS, Hasso M, Kumbar L. Hepatotoxicity induced by MK-677. BMJ Case Reports. 2025;18(7) doi:10.1136/bcr-2025-265728 · PMID: 40675653
  15. Tewari K, Liu TP, Im C, Hamad C, Petrigliano F, Cheung EC. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. American Journal of Sports Medicine. 2026 doi:10.1177/03635465261464420 · PMID: 42578445
  16. Campbell GA, Patrie JT, Gaylinn BD, Thorner MO, Bolton WK. Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study. Nephrology Dialysis Transplantation. 2018;33(3) :523-530 doi:10.1093/ndt/gfw474 · PMID: 28340044
  17. Constanzer ML, Chavez-Eng CM, Matuszewski BK. Determination of a novel growth hormone secretagogue (MK-677) in human plasma at picogram levels by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. Journal of chromatography. B, Biomedical sciences and applications. 1997;693(1) :131-7 doi:10.1016/s0378-4347(97)00035-2 · PMID: 9200526
Published: 2026-07-25Last updated: 2026-11-06
  • Correction (2026-11-06): Corrected 6 November 2026 after a dose and citation audit: an unsourced human half-life was removed; a bone-density result was corrected; trial results, heart failure and glucose signals and FDA's safety statement were added; legal statements were replaced with sourced facts.

If you spot an error or have new evidence to suggest, please use our corrections policy.

Continue reading